Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Elda Righi et al.|JAMA|2018Cited by 761
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N. A. Harris, David L. Paterson, Anton Y. Peleg et al.|Trials|2015Cited by 73
Use of an Innovative Personality-Mindset Profiling Tool to Guide Culture-Change Strategies among Different Healthcare Worker GroupsM. Lindsay Grayson, Marilyn Cruickshank, Nenad Maćešić et al.|PLoS ONE|2015Cited by 61
Microbial Ecological Signatures Predict Pathogen Emergence and Multidrug Resistance in Cystic Fibrosis Airways up to a Year in AdvanceThomas Goddard, Robert A. Edwards, Jessica AP Carlson-Jones et al.|medRxiv|2026Cited by 0